



### I. Epidemiological profile

Population (UN Population Division)	2012	%
High transmission (>1 case per 1000 population)	19 500 000	37
Low transmission (0–1 cases per 1000 population)	12 100 000	23
Malaria-free (0 cases)	21 100 000	40
Total	52 700 000	

Parasites and vectors	
Major plasmodium species:	<i>P. falciparum</i> (65%), <i>P. vivax</i> (35%)
Major anopheles species:	<i>An. minimus</i> , <i>dirus</i>
Programme phase: Control	

### II. Intervention policies and strategies



Intervention	Policies/strategies	Yes/No	Year adopted
<b>ITN</b>	ITNs/LLINs distributed free of charge	Yes	2003
	ITNs/LLINs distributed to all age groups	Yes	2003
<b>IRS</b>	IRS is recommended	Yes	–
	DDT is used for IRS	Yes	–
<b>Larval control</b>	Use of larval control	No	–
<b>IPT</b>	IPT used to prevent malaria during pregnancy	N/A	–
<b>Diagnosis</b>	Patients of all ages should receive diagnostic test	Yes	–
	Malaria diagnosis is free of charge in the public sector	Yes	–
<b>Treatment</b>	ACT is free for all ages in public sector	Yes	–
	Artemisinin-based monotherapies withdrawn	No	–
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for <i>P. falciparum</i>	Yes	2010
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	–
	G6PD test is a requirement before treatment with primaquine	No	–
	Directly observed treatment with primaquine is undertaken	No	–
System for monitoring of adverse reaction to antimalarials exists	Yes	–	

Intervention	Policies/strategies	Yes/No	Year adopted
<b>Surveillance</b>	ACD for case investigation (reactive)	No	–
	ACD at community level of febrile cases (pro-active)	No	–
	Mass screening is undertaken	No	–
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	–
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	–



Antimalarial treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	–	–
First-line treatment of <i>P. falciparum</i>	AL; AM; AS+MQ; DHA-PPQ; PQ	2008
For treatment failure of <i>P. falciparum</i>	AS+D; AS+T	2008
Treatment of severe malaria	AM; AS; QN	2008
Treatment of <i>P. vivax</i>	CQ+PQ(14d)	2008
Dosage of primaquine for radical treatment of <i>P. vivax</i>	0.25 mg/kg (14 days)	
Type of RDT used	<i>Pf</i> + <i>Pv</i> specific (Combo)	

Therapeutic efficacy tests (clinical and parasitological failure, %)							
Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
DHA-PPQ	2005–2011	0	0.7	5	28 days	14	<i>P.f</i>
AL	2007–2011	0	0	5.9	28 days	13	<i>P.f</i>





### III. Financing



### IV. Coverage



### V. Impact



**Impact:** Insufficiently consistent data to assess trends